Search results for "Receptor"

showing 10 items of 6990 documents

TMS-EEG signatures of glutamatergic neurotransmission in human cortex

2019

AbstractNeuronal activity in the brain is regulated by an excitation-inhibition balance. Glutamate is the main excitatory neurotransmitter. Transcranial magnetic stimulation (TMS) evoked electroencephalographic (EEG) potentials (TEPs) represent a novel way to quantify pharmacological effects on neuronal activity in the human cortex. Here we tested TEPs under the influence of a single oral dose of two anti-glutamatergic drugs, perampanel, an AMPA-receptor antagonist, and dextromethorphan, an NMDA-receptor antagonist, and nimodipine, an L-type voltage-gated calcium channel blocker in 16 healthy adults in a pseudorandomized, double-blinded, placebo-controlled, crossover design. Single-pulse TM…

medicine.diagnostic_testbusiness.industrymedicine.medical_treatmentGlutamate receptorElectroencephalographyNeurotransmissionTranscranial magnetic stimulationGlutamatergicPerampanelchemistry.chemical_compoundmedicine.anatomical_structurechemistrynervous systemCortex (anatomy)medicinePremovement neuronal activitybusinessNeuroscience
researchProduct

The affinities of monoclonal antibodies against core antigen of hepatitis B virus

1994

Four monoclonal antibodies generated against the recombinant core antigen of hepatitis B virus are investigated for antigen binding. All exhibit a similar affinity to polystyrene-sorbed antigen but only one of them interacts with native form of HBcAg (an assembled particle) in solution. The presence of 0.1% sodium dodecylsulphate is required for the binding of other three antibodies. The phenomenon can be interpreted as inaccessibility of the corresponding epitopes unless the multimeric antigen structure is disrupted. The core antigen coated on polystyrene is considered as a similar exposed structure.

medicine.drug_classAntibody AffinityBiologyAntibodies Viralmedicine.disease_causeMonoclonal antibodyEpitopeEpitopesMiceAntigenVirologymedicineAnimalsHepatitis B virusHybridomasT-cell receptorAntibodies MonoclonalSodium Dodecyl SulfateGeneral Medicinebiology.organism_classificationHepatitis B Core AntigensVirologyMolecular biologyRecombinant ProteinsHBcAgHepadnaviridaebiology.proteinAntibodyArchives of Virology
researchProduct

Carcinogenic aspect of xenobiotic molecules belonging to the peroxisome proliferator family.

1999

It is known that a short-term exposure of rat, mice or incubation of hepatic cells with fibrate molecules leads to increase in peroxisome number and cell hyperplasia. Further, long-term incubation of cells (at least a year) show transformed characteristics with foci and nodules. To explain the hepatocarcinogenic effect of peroxisome proliferators in rodents we studied the effect of peroxisome proliferators on rat liver oncogenes expression. Earlier, we reported an increase in liver and kidney mRNA level of c-myc and N-myc. Since several metabolic genes are activated by PPAR (peroxisome proliferators activated receptor) through a PPRE (peroxisome proliferator response element), we suggest th…

medicine.drug_classCarcinogenicity TestsResponse elementGuinea PigsPeroxisome proliferator-activated receptorPeroxisome ProliferationRodentiaFibrateBiologyXenobioticsGeneticsmedicineTumor Cells CulturedAnimalsHumansReceptorchemistry.chemical_classificationGeneral MedicineOncogenesPeroxisomeMolecular biologyCell biologyRatsCell Transformation NeoplasticchemistryHepatic stellate cellCarcinogensPeroxisome ProliferatorsCiprofibrateCell Divisionmedicine.drugHepatomegalyInternational journal of molecular medicine
researchProduct

Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer

2019

There is still a great unmet medical need concerning diagnosis and treatment of breast cancer which could be addressed by utilizing specific molecular targets. Tumor-associated MUC1 is expressed on over 90 % of all breast cancer entities and differs strongly from its physiological form on epithelial cells, therefore presenting a unique target for breast cancer diagnosis and antibody-mediated immune therapy. Utilizing an anti-tumor vaccine based on a synthetically prepared glycopeptide, we generated a monoclonal antibody (mAb) GGSK-1/30, selectively recognizing human tumor-associated MUC1. This antibody targets exclusively tumor-associated MUC1 in the absence of any binding to MUC1 on health…

medicine.drug_classEstrogen receptorMUC1Breast NeoplasmsMice TransgenicDeferoxamineMonoclonal antibody89Zr03 medical and health sciences0302 clinical medicineBreast cancerIn vivoCell Line TumorBiomarkers TumormedicineAnimalsHumansTissue Distributionskin and connective tissue diseasesMUC1Triple-negative breast cancermAbRadioisotopesMice Inbred BALB Cbiologybusiness.industryMucin-1breast cancer diagnosisAntibodies MonoclonalCancerGeneral MedicinePrognosismedicine.diseaseImmunohistochemistryMice Inbred C57BLPositron-Emission Tomographybiology.proteinCancer researchFemale030211 gastroenterology & hepatologyZirconiumAntibodybusinessResearch PaperInternational Journal of Medical Sciences
researchProduct

Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps

2013

Background A number of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) are resistant to oral corticosteroids. Mucin 1 (MUC1) shows anti-inflammatory properties, and its cytoplasmic tail (CT) interacts with transcription factors, facilitating their nuclear translocation. Because glucocorticoid receptor (GR) nuclear translocation is key to the anti-inflammatory effect of corticosteroids, we hypothesized that MUC1 is involved in the effectiveness of corticosteroids. Objective To analyze the role of MUC1 in corticosteroid effectiveness in different cohorts of patients with CRSwNP and elucidate the possible mechanisms involved. Methods Seventy-three patients with CRSwNP took oral…

medicine.drug_classImmunologyAnti-Inflammatory AgentsDrug ResistanceDown-Regulationdigestive systemNasal PolypsReceptors GlucocorticoidGlucocorticoid receptorDownregulation and upregulationAdrenal Cortex HormonesmedicineHumansImmunology and AllergyNasal polypsSinusitisskin and connective tissue diseasesneoplasmsDexamethasoneMUC1Rhinitisbusiness.industryMucin-1Toll-Like ReceptorsMucinmedicine.diseasebiological factorsdigestive system diseasesNasal MucosaGene Expression RegulationChronic DiseaseImmunologyImmunohistochemistryCorticosteroidbusinessSignal Transductionmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

General considerations in the interpretation of I-J genetic restrictions: evidence that the antigen-binding chain of antigen-specific T-suppressor fa…

1987

SUMMARY (CBA × B10)F1 [(H-2k x H-2b)] mice produce two types of antigen-specific T-suppressor factor (TsF), which can be separated by affinity chromatography on anti-I-J monoclonal antibody. After reduction and alkylation, both chains of F1 TsF are required for biological activity. However, the antigen-binding chain (AgBC) of F1 TsFk (AgBCk) is only complemented by I-Jk and likewise for F1 TsFb. In other words, interchain complementation shows the same genetic restriction in interchain complementation in parental and F1 mice. F1 TsF bearing, for example, I-Jk (TsFk), interacts with haptenized ‘antigen-presenting cells’ (‘APC’) of both parental haplotypes, and may be described as showing dua…

medicine.drug_classImmunologyAntigen-Presenting CellsImmunogeneticsBiologyMonoclonal antibodyModels BiologicalEpitopesMiceStructure-Activity RelationshipAntigenAffinity chromatographySpecies SpecificityGeneticsmedicineSuppressor Factors ImmunologicAnimalsBinding siteReceptorCrosses GeneticGeneticsBinding SitesHaplotypeGenetic Complementation TestHistocompatibility Antigens Class IIComplementationHaplotypesJournal of immunogenetics
researchProduct

Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

2016

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kinetics studies showed very different stabilities over 24 h; however, fast reductive activation via E. coli nitroreductase could be confirmed for both panels. The anticancer activity and signaling inhibition of the compounds against various human cancer cell lines were evaluated in cell culture. These data, together with molecular docking simulations, revealed distinct differences in the impact of …

medicine.drug_classPharmacology010402 general chemistry01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitor03 medical and health sciencesNitroreductase0302 clinical medicinetyrosine kinase inhibitorsDrug DiscoverymedicinecancerEpidermal growth factor receptorGeneral Pharmacology Toxicology and PharmaceuticsPharmacologybiologyhypoxiaSunitinibChemistryOrganic ChemistryProdrugtargeted therapeutic0104 chemical sciencesSettore CHIM/03 - Chimica Generale E InorganicaCell culture030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibprodrugTyrosine kinasemedicine.drugChemMedChem
researchProduct

Demonstration of P29, an oestrogen receptor-associated tumor marker, in human term placenta.

1991

A Mr29,000 serine phosphoprotein (P29) related to oestradiol receptor was studied in human term placenta with the use of a specific monoclonal antibody (D5). D5 was used with two different methods, immunohistochemistry and immunoradiometry. For immunohistochemistry, an indirect immunoperoxidase method was chosen to detect P29 in methacarn-fixed, wax-embedded sections. P29 was mostly confined to the syncytiotrophoblast surrounding placental villi, staining being positive in both cytoplasm and nuclei. The stroma of villi was negative. Content of P29 was uniformly high in crude placental cytosol, as measured by immunoradiometry assays. Specificity of D5 against P29 in placenta was tested by an…

medicine.drug_classPlacentaBiologyMonoclonal antibodySyncytiotrophoblastPregnancyPlacentamedicineBiomarkers TumorSerineHumansHeat-Shock ProteinsImmunoperoxidaseObstetrics and GynecologyAntibodies MonoclonalPhosphoproteinsMolecular biologyImmunohistochemistryStainingTrophoblastsmedicine.anatomical_structureReproductive MedicineReceptors EstrogenCytoplasmPhosphoproteinembryonic structuresImmunohistochemistryFemaleImmunoradiometric AssayDevelopmental BiologyPlacenta
researchProduct

Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Ac…

2019

The most frequently diagnosed cancers in women are the estrogen receptor (ER)-positive breast cancer subtypes, which are characterized by estrogen dependency for their growth. The mainstay of clinical treatment for this tumor relies on the modulation of ER action or on the suppression of estrogen biosynthesis via the administration of Selective ERα Modulators/Down-regulators (SERMs/SERDs) or aromatase inhibitors, respectively. Nevertheless, de novo and acquired resistance to these therapies frequently occurs and represents a major clinical concern for patient survival. Recently, somatic mutations affecting the hormone-binding domain of ERα (i. e. Y537S, Y537N, D538G) have been associated w…

medicine.drug_classSomatic cellIn silicoEstrogen receptor-02 engineering and technology010402 general chemistry01 natural scienceslcsh:ChemistryBreast cancerbreast cancermedicineAromataseresistant breast cancersOriginal ResearchbiologyChemistryWild typeY537SGeneral Chemistry021001 nanoscience & nanotechnologyAntiestrogenmedicine.diseaseSERMmolecular dynamics0104 chemical sciencesChemistrylcsh:QD1-999EstrogenSERDbiology.proteinCancer research0210 nano-technologyestrogen receptorFrontiers in chemistry
researchProduct

Novel Approaches for Immunosuppression in Graves’ Hyperthyroidism and Associated Orbitopathy

2020

<b><i>Background:</i></b> Both Graves’ hyperthyroidism (GH) and Graves’ orbitopathy (GO) are associated with significant adverse health consequences. All conventional treatment options have limitations regarding efficacy and safety. Most importantly, they do not specifically address the underlying immunological mechanisms. We aim to review the latest development of treatment approaches in these two closely related disorders. <b><i>Summary:</i></b> Immunotherapies of GH have recently demonstrated clinical efficacy in preliminary studies. They include ATX-GD-59, an antigen-specific immunotherapy which restores immune tolerance to the thyrotropin…

medicine.drug_classTeprotumumabbusiness.industryEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismImmunosuppressionImmunotherapyMonoclonal antibodyImmune toleranceThyrotropin receptor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTocilizumabchemistry030220 oncology & carcinogenesisImmunologymedicineRituximabbusinessResearch Articlemedicine.drugEuropean Thyroid Journal
researchProduct